FDA is hoping to provide Manufacturers of minimally invasive glaucoma surgical (MIGS) devices with a more clear-cut path to market with a newly finalized FDA guidance document .
FDA considers the document a “leap frog guidance,” meaning it provides initial recommendations on an emerging medical device technology and may be updated as more information becomes available
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?